2.50
Hdl Handle:
http://hdl.handle.net/10755/621644
Category:
Full-text
Format:
Text-based Document
Type:
Presentation
Level of Evidence:
N/A
Research Approach:
N/A
Title:
Personalized Pediatric Pain Management: Myth or Reality?
Other Titles:
Perspectives on Pediatric Health
Author(s):
Mele, Cheryl
Lead Author STTI Affiliation:
Gamma
Author Details:
Cheryl Mele, DNP, PNP, AC/PC-BC, NNP-BC, Professional Experience: 1991-2013-- PNP/NNP Thomas Jefferson University Hospital and A-I Dupont Children Hospital -- NICU -- outpatient primary care --- infant high risk clinic 2010-- current PNP Pain Management Team CHOP 2004- current- Assistant Professor Pediatric Nurse Practitioner Program --Authored and coauthored numerous publications on pediatric genetic research and new technologies --Provided numerous presentations at national and international scientific meetings on current genetic research and evidence base practice Author Summary: The presenter is a pediatric nurse practitioner for over 20 years and assistant professor at a major university. She has authored or co-authored numerous publications/ book chapters on the topic of pediatric genetic research. The presenter offers experience in a variety of pediatric settings such as acute care, high-risk follow-up and primary care. Currently, the presenter practices in a pediatric pain management team in one of the premier institutions in the USA.
Abstract:

For a child undergoing a surgical procedure or issues with chronic pain, an essential goal is to obtain optimal pain management without significant adverse effects. Regretfully, safe and operative analgesia is an indefinable medical objective. Pain management within the pediatric realm reports that 50% pediatric perioperative pain experience will be efficient and acquire minimal side effects from opioids (Sadhasivam et al., 2014), It is well known that poor pain control can harvest physical difficulties, prolonged post-op recovery, and long-term behavioral complications. Still there is an extensive range of reactions to opioids secondary to variability in patient’s gender, ethnicity, development, co-morbidities and genetic factors. Research demonstrates that up to two-thirds of the unpredictability in pain perception and differences in the effectiveness of analgesic drugs are partly genetically predetermined (Cregg, et al., 2013).

Since the completion of the Human Genome and Hap Map Project the era of personalized medicine is upon us. Sequencing of the entire human genome has brought about a progression of knowledge regarding drug therapies, genetic predisposition and environmental impact such as epigenetics. Every individual has a distinctive genetic code. Pharmacogenomics is the study of how disparities in the human genome ultimately affect the response to medications and offer different views into the variability observed within individuals prescribed opioids for pain management (Jannetto & Bratanow, 2011). Pharmacogenomics seeks to link differences in gene structure or genotype (polymorphisms) with pharmacologic differences in drug action (phenotype) (Galinkin, et al, 2010). Pharmacogenomics primarily is split into two parts describing genetic variants involving pharmacokinetics (absorption, distribution, metabolism and elimination of a drug) and pharmacodynamics (an activity of the drug at the target site/receptor of a drug (Janicki, 2013; Jannetto & Bratanow, 2011).

Opioids are standard treatments for chronic and post-operative pain. Reports of prescription opiate misuse in adolescence and adult population is predominant in the media. The concern in healthcare providers and families is fear of exposure to prescribed opioid prescription drugs may be a catalyst for addiction Hence, pain pharmacogenomics has held promise to provide information on one’s genome , identify patients at risk for complications or inadequate response to pain pharmacotherapy . The purpose of this presentation is to explore the genetic science involved with drug and individual variability which can aid nurses to support patient/families in developing guidelines towards a personalized pain management plan based upon one's genome.

Keywords:
Pain Management; Pediatric; Pharmacogenomics
Repository Posting Date:
3-Jul-2017
Date of Publication:
3-Jul-2017
Other Identifiers:
INRC17E04
Conference Date:
2017
Conference Name:
28th International Nursing Research Congress
Conference Host:
Sigma Theta Tau International
Conference Location:
Dublin, Ireland
Description:
Event Theme: Influencing Global Health Through the Advancement of Nursing Scholarship

Full metadata record

DC FieldValue Language
dc.language.isoen_USen
dc.type.categoryFull-texten
dc.formatText-based Documenten
dc.typePresentationen
dc.evidence.levelN/Aen
dc.research.approachN/Aen
dc.titlePersonalized Pediatric Pain Management: Myth or Reality?en_US
dc.title.alternativePerspectives on Pediatric Healthen
dc.contributor.authorMele, Cherylen
dc.contributor.departmentGammaen
dc.author.detailsCheryl Mele, DNP, PNP, AC/PC-BC, NNP-BC, Professional Experience: 1991-2013-- PNP/NNP Thomas Jefferson University Hospital and A-I Dupont Children Hospital -- NICU -- outpatient primary care --- infant high risk clinic 2010-- current PNP Pain Management Team CHOP 2004- current- Assistant Professor Pediatric Nurse Practitioner Program --Authored and coauthored numerous publications on pediatric genetic research and new technologies --Provided numerous presentations at national and international scientific meetings on current genetic research and evidence base practice Author Summary: The presenter is a pediatric nurse practitioner for over 20 years and assistant professor at a major university. She has authored or co-authored numerous publications/ book chapters on the topic of pediatric genetic research. The presenter offers experience in a variety of pediatric settings such as acute care, high-risk follow-up and primary care. Currently, the presenter practices in a pediatric pain management team in one of the premier institutions in the USA.en
dc.identifier.urihttp://hdl.handle.net/10755/621644-
dc.description.abstract<p><span>For a child undergoing a surgical procedure or issues with chronic pain, an essential goal is to obtain optimal pain management without significant</span><strong> </strong><span>adverse effects. Regretfully, safe and operative analgesia is an indefinable medical objective. Pain management within the pediatric realm reports that 50% pediatric perioperative pain experience will be efficient and acquire minimal side effects from opioids (Sadhasivam et al., 2014), It is well known that poor pain control can harvest physical difficulties, prolonged post-op recovery, and long-term behavioral complications. Still there is an extensive range of reactions to opioids secondary to variability in patient’s gender, ethnicity, development, co-morbidities and genetic factors. Research demonstrates that up to two-thirds of the unpredictability in pain perception and differences in the effectiveness of analgesic drugs are partly genetically predetermined (Cregg, et al., 2013).</span></p> <p>Since the completion of the Human Genome and Hap Map Project the era of personalized medicine is upon us. Sequencing of the entire<strong> </strong>human genome has brought about a progression of knowledge regarding drug therapies, genetic predisposition and environmental impact such as epigenetics. Every individual has a distinctive genetic code. Pharmacogenomics is the study of how disparities in the human genome ultimately affect the response to medications and offer different views into the variability observed within individuals prescribed opioids for pain management (Jannetto & Bratanow, 2011). Pharmacogenomics seeks to link differences in gene structure or genotype (polymorphisms) with pharmacologic differences in drug action (phenotype) (Galinkin, et al, 2010). Pharmacogenomics primarily is split into two parts describing genetic variants involving pharmacokinetics (absorption, distribution, metabolism and elimination of a drug) and pharmacodynamics (an activity of the drug at the target site/receptor of a drug (Janicki, 2013; Jannetto & Bratanow, 2011).</p> <p>Opioids are standard treatments for chronic and post-operative pain. Reports of prescription opiate misuse in adolescence and adult population is predominant in the media. The concern in healthcare providers and families is fear of exposure to prescribed opioid prescription drugs may be a catalyst for addiction Hence, pain pharmacogenomics has held promise to provide information on one’s genome , identify patients at risk for complications or inadequate response to pain pharmacotherapy . The purpose of this presentation is to explore the genetic science involved with drug and individual variability which can aid nurses to support patient/families in developing guidelines towards a personalized pain management plan based upon one's genome.</p>en
dc.subjectPain Managementen
dc.subjectPediatricen
dc.subjectPharmacogenomicsen
dc.date.available2017-07-03T18:13:56Z-
dc.date.issued2017-07-03-
dc.date.accessioned2017-07-03T18:13:56Z-
dc.conference.date2017en
dc.conference.name28th International Nursing Research Congressen
dc.conference.hostSigma Theta Tau Internationalen
dc.conference.locationDublin, Irelanden
dc.descriptionEvent Theme: Influencing Global Health Through the Advancement of Nursing Scholarshipen
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.